HKHye Jin Kim

Hye Jin Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hye Jin Kim has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Keun-Hong Park

    Department of Nano-regenerative Medical Engineering, College of Life Science, CHA University, 6F, CHA Biocomplex, Sampyeong-Dong, Bundang-gu, Seongnam-si, 13488, Republic of Korea

    6 shared publications
  • Hui Bang Cho

    Laboratory of Nano-regenerative Medicine, Department of Biomedical Science, College of Life Science, CHA University, CHA Biocomplex, Sampyeong-Dong, Bundang-gu, Seongnam-si, 13488, Republic of Korea

    5 shared publications
  • Sujeong Lee

    Laboratory of Nano-regenerative Medicine, Department of Biomedical Science, College of Life Science, CHA University, CHA Biocomplex, Sampyeong-Dong, Bundang-gu, Seongnam-si, 13488, Republic of Korea

    5 shared publications
  • Gyuwon So

    Laboratory of Nano-regenerative Medicine, Department of Biomedical Science, College of Life Science, CHA University, CHA Biocomplex, Sampyeong-Dong, Bundang-gu, Seongnam-si, 13488, Republic of Korea

    4 shared publications
  • Chae Won Cho

    Laboratory of Nano-regenerative Medicine, Department of Biomedical Science, College of Life Science, CHA University, CHA Biocomplex, Sampyeong-Dong, Bundang-gu, Seongnam-si, 13488, Republic of Korea

    3 shared publications
  • Hye‐Ryoung Kim

    School of Bioconvergence CHA University 6F, CHA Biocomplex, Sampyeong‐Dong, Bundang‐gu Seongnam‐si 13488 Republic of Korea

    2 shared publications

Latest Publications

  • Open Access

    Tumor-targeted liposomal RNAi therapy suppresses breast cancer and modulates tumor microenvironment

    by Sujeong Lee, Seung Hee Choi, Hui Bang Cho, Chae Won Cho, Jungsun Lee, Gyuwon So, Hye Jin Kim, Kyung-Soon Park, Keun-Hong Park

    Liposomes are widely used nanocarriers, but their clinical translation remains limited by poor tumor selectivity and inefficient nucleic acid delivery. To address these challenges, we designed multifunctional liposomes incorporating phenylboronic acid (PBA) for tumor targeting, ginsenoside Rh2 (Rh2) as both a cholesterol-mimetic stabilizer and intrinsic anticancer agent, and small interfering RNA against vascular endothelial growth factor (VEGF). VEGF was selected for its pivotal role in tumor angiogenesis and to counteract the paradoxical pro-angiogenic effect of Rh2. PBA-modified liposomes exhibited enhanced tumor accumulation and cellular uptake compared with non-targeted controls. Rh2 induced direct cytotoxicity, while VEGF silencing further suppressed angiogenesis together producing synergistic antitumor activity. In vivo, Rh2-PBA-siVEGF liposomes (RhPLIPO-siVEGF) and Rh2-PBA-Negative Control siRNA (siNC) liposomes (RhPLIPO-siNC) were evaluated in a 4T1 orthotopic breast tumor model. Both formulations elicited effects characterized by increased infiltration of T cells and M1 macrophages. Notably, RhPLIPO-siVEGF treatment significantly reduced tumor growth and microvascular density compared with RhPLIPO-siNC, confirming synergy between Rh2-mediated cytotoxicity and VEGF knockdown. Overall, this multifunctional liposomal system integrates tumor targeting, intrinsic cytotoxicity, and RNA interference-mediated anti-angiogenesis with minimal adverse effects, offering a potent and versatile nanoplatform for targeted breast cancer therapy.

  • Open Access

    Orally delivered, pH-resistant dual coated extracellular vesicles restore intestinal barrier function and suppress colitis

    by Chae Won Cho, Jaewon Roh, Sujeong Lee, Hui Bang Cho, Jungsun Lee, Gyuwon So, Kun Na, Hye Jin Kim, Keun-Hong Park


  • Open Access

    Near Infrared‐Mediated Intracellular NADH Delivery Strengthens Mitochondrial Function and Stability in Muscle Dysfunction Model

    by Hui Bang Cho, Hye‐Ryoung Kim, Sujeong Lee, Chae Won Cho, Ji‐In Park, Seulki Youn, Gyuwon So, Sumin Kang, Hye Jin Kim, Keun‐Hong Park

    Mitochondrial transfer emerges as a promising therapy for the restoration of mitochondrial function in damaged cells, mainly due to its limited immunogenicity. However, isolated mitochondria rapidly lose function because they produce little energy outside cells. Therefore, this study investigates whether near infrared (NIR)‐mediated nicotinamide adenine dinucleotide (NADH) pre‐treatment enhances mitochondrial function and stability in mitochondria‐donor cells prior to transplantation. Clinical applications of NADH, an essential electron donor in the oxidative phosphorylation process, are restricted due to the limited cellular uptake of NADH. To address this, a photo‐mediated method optimizes direct NADH delivery into cells and increases NADH absorption. L6 cells treated with NADH and irradiated with NIR enhanced NADH uptake, significantly improving mitochondrial energy production and function. Importantly, the improved functional characteristics of the mitochondria are maintained even after isolation from cells. Primed mitochondria, i.e., those enhanced by NIR‐mediated NADH uptake (P‐MT), are encapsulated in fusogenic liposomes and delivered into muscle cells with mitochondrial dysfunction. Compared to conventional mitochondria, P‐MT mitochondria promote greater mitochondrial recovery and muscle regeneration. These findings suggest that NIR‐mediated NADH delivery is an effective strategy for improving mitochondrial function, and has the potential to lead to novel treatments for mitochondrial disorders and muscle degeneration.


  • Open Access

    Osteoblast‐Derived Mitochondria Formulated with Cationic Liposome Guide Mesenchymal Stem Cells into Osteogenic Differentiation

    by Hye‐Ryoung Kim, Seonjeong Woo, Hui Bang Cho, Sujeong Lee, Chae Won Cho, Ji‐In Park, Seulki Youn, Gyuwon So, Sumin Kang, Sohyun Hwang, et al.

    While mitochondria are known to be essential for intracellular energy production and overall function, emerging evidence highlights their role in influencing cell behavior through mitochondrial transfer. This phenomenon provides a potential basis for the development of treatment strategies for tissue damage and degeneration. This study aims to evaluate whether mitochondria isolated from osteoblasts can promote osteogenic differentiation in mesenchymal stem cells (MSCs). Mitochondria from MSCs, which primarily utilize glycolysis, are compared with those from MG63 cells, which depend on oxidative phosphorylation. Mitochondria from both cell types are then encapsulated in cationic liposomes and transferred to MSCs, and their impact on differentiation is assessed. Mitochondria delivery from MG63 cells to MSCs grown in both two‐ and three‐dimensional cultures results in increased expression of osteogenic markers, including Runt‐related transcription factor 2, Osterix, and Osteopontin, and upregulation of genes involved in Bone morphogenetic protein 2 signaling and calcium import. This is accompanied by increased calcium influx and regulated by the Wnt/β‐catenin signaling pathway. Transplantation of spheroids containing MSCs with MG63‐derived mitochondria in bone defect animal models improves bone regeneration. The results suggest that delivery of MG63‐derived mitochondria effectively guides MSCs toward osteogenesis, paving the way for the development of mitochondria‐transplantation therapies.


  • Open Access

    Fusogenic liposomes encapsulating mitochondria as a promising delivery system for osteoarthritis therapy

    by Hye-Ryoung Kim, Hui Bang Cho, Sujeong Lee, Ji-In Park, Hye Jin Kim, Keun-Hong Park


  • Open Access

    Gene expression profiling of chondrogenic differentiation by dexamethasone-conjugated polyethyleneimine with SOX trio genes in stem cells

    by Se Won Yi, Hye Jin Kim, Hyun Jyung Oh, Heejun Shin, Jung Sun Lee, Ji Sun Park, Keun-Hong Park

    During differentiation of stem cells, it is recognized that molecular mechanisms of transcription factors manage stem cells towards the intended lineage. In this study, using microarray-based technology, gene expression profiling was examined during the process of chondrogenic differentiation of human mesenchymal stem cells (hMSCs). To induce chondrogenic differentiation of hMSCs, the cationic polymer polyethyleneimine (PEI) was coupled with the synthetic glucocorticoid dexamethasone (DEX). DEX/PEI could be polyplexed with anionic plasmid DNAs (pDNAs) harboring the chondrogenesis-inducing factors SOX5, SOX6, and SOX9. These are named differentiation-inducing nanoparticles (DI-NPs). A DI-NP system for inducing chondrogenic differentiation was designed and characterized by dynamic light scattering and scanning electron microscopy (SEM). Chondrogenic induction of hMSCs was evaluated using various tools such as reverse-transcription polymerase chain reaction (RT-PCR), Western blotting, confocal fluorescent microscopy, and immunohistochemistry analysis. The gene expression profiling of DI-NP-treated hMSCs was performed by microarray analysis. The hMSCs were more efficiently transfected with pDNAs using DI-NPs than using PEI. Moreover, microarray analysis demonstrated the gene expression profiling of hMSCs transfected with DI-NPs. Chondrogenic factors including SOX9, collagen type II (COLII), Aggrecan, and cartilage oligometric matrix protein (COMP) were upregulated while osteogenic factors including collagen type I (COLI) was downregulated. Chondrogenesis-induced hMSCs were better differentiated as assessed by RT-PCR, Western blotting analyses, and immunohistochemistry. DI-NPs are good gene delivery carriers and induce chondrogenic differentiation of hMSCs. Additionally, comprehensive examination of the gene expression was attempted to identify specific genes related to differentiation by microarray analysis.